Back to top
more

Hologic, Inc. (HOLX)

(Real Time Quote from BATS)

$49.47 USD

49.47
356,628

-0.25 (-0.50%)

Updated Sep 16, 2019 12:12 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.58%
17.73%
9.37%
4.95%
1.76%
10.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | A Growth | A Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Hologic (HOLX) Stock Now

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

HOLX MDT BAX NUVA

Zacks Equity Research

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DXCM SARTF MASI HOLX

Zacks Equity Research

Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

ISRG HOLX BAX SYK

Zacks Equity Research

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

Solid growth in emerging markets is expected to be an added positive this earnings season.

HOLX MASI DXCM MCK LIVN

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

TFX HOLX ILMN XRAY

Zacks Equity Research

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

TFX HOLX XRAY GNC

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

TFX HOLX ZBH XRAY

Zacks Equity Research

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell (OMCL) aims at product innovation through R&D.

OMCL TFX HOLX XRAY

Zacks Equity Research

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

TFX HOLX SYK XRAY

Zacks Equity Research

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

TFX HOLX MMSI XRAY

Zacks Equity Research

Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand

It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.

TFX HOLX CHE XRAY

Zacks Equity Research

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.

TFX HOLX RMD XRAY

Zacks Equity Research

LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall

While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.

TFX HOLX XRAY LH

Zacks Equity Research

Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.

TFX HOLX ALGN XRAY

Zacks Equity Research

Integra Lifesciences' (IART) Earnings Top Estimates in Q2

We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.

TFX HOLX IART XRAY

Zacks Equity Research

Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View

Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.

TFX HOLX BAX XRAY

Zacks Equity Research

NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y

NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.

TFX HOLX XRAY NXGN

Zacks Equity Research

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.

TFX VAR HOLX XRAY

Zacks Equity Research

Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss

Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.

CERN TFX HOLX XRAY

Zacks Equity Research

Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance

Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.

TMO TFX HOLX XRAY

Zacks Equity Research

Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss

Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.

TFX HOLX NEOG XRAY

Zacks Equity Research

Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines

Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.

TFX HOLX BSX XRAY

Zacks Equity Research

Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2

Medidata (MDSO) gains from solid segmental contributions in Q2.

MDSO TFX HOLX XRAY

Zacks Equity Research

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HOLX

Zacks Equity Research

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.

TFX HOLX EW XRAY